Ascendis Pharma A/S (NASDAQ:ASND) Earns “Overweight” Rating from Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They presently have a $300.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 33.16% from the company’s current price.

ASND has been the topic of several other research reports. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Raymond James Financial lowered Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 target price for the company. in a research report on Tuesday, September 15th. TD Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Stifel Nicolaus decreased their price target on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $310.75.

Ascendis Pharma A/S Trading Down 0.1%

Shares of NASDAQ:ASND traded down $0.31 during midday trading on Friday, hitting $225.29. 28,915 shares of the stock were exchanged, compared to its average volume of 694,392. The business’s 50-day moving average price is $251.52 and its 200 day moving average price is $242.29. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of 17.52 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Analysts predict that Ascendis Pharma A/S will post 3.69 earnings per share for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares in the company, valued at approximately $714,357. This represents a 222.22% increase in their position. The SEC filing for this purchase provides additional information. 40.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Ascendis Pharma A/S during the fourth quarter worth approximately $42,000. Allworth Financial LP lifted its stake in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 122 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares in the last quarter. Finally, IFP Advisors Inc grew its position in shares of Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after buying an additional 419 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.